CSL Share Price Performance

CSL Community Fair Values

AN
AnalystConsensusTarget
Consensus Narrative from 17 Analysts
Advancements In iNOMi Technology And HEMGENIX Will Strengthen Market Position
Key Takeaways Advancements in plasma collection and operational efficiencies are set to reduce costs and improve CSL Behring's margins, potentially boosting overall earnings. Product rollouts and expanded market approvals, especially in HAE therapy, aim to drive revenue growth and offset vaccine sector challenges.
AU$312.60
FV
15.5% undervalued intrinsic discount
6.83%
Revenue growth p.a.
2users have liked this narrative
0users have commented on this narrative
107users have followed this narrative
4 days ago author updated this narrative
RA
Ramsee
Community Contributor
CSL is undervalued in High Tax Scenario
CSL Limited: Fair Value Assessment Amidst Evolving US Tariff Scenarios Executive Summary This report provides an assessment of the fair value of CSL Limited (CSL) under various potential United States (US) tariff scenarios. CSL, a global biotechnology leader with significant operations in plasma therapies (CSL Behring), influenza vaccines (CSL Seqirus), and iron/nephrology treatments (CSL Vifor), faces potential impacts from evolving US trade policies.
AU$263.33
FV
0.3% overvalued intrinsic discount
6.00%
Revenue growth p.a.
3users have liked this narrative
4users have commented on this narrative
43users have followed this narrative
4 months ago author updated this narrative

View all narratives

Recent CSL News & Updates

No updates

CSL Limited Key Details

Last Reported Earnings

Dec 31, 2024

Next Reporting Earnings

Aug 19, 2025

Earnings per share (EPS): 5.68
Gross Margin: 52.23%
Net Profit Margin: 18.04%
Debt/Equity Ratio: 50.4%

View full report ›

CSL Limited Competitors

View more competitors

About CSL

Founded: 1916
Employees: 32698
CEO: Paul McKenzie
WebsiteView website: www.csl.com.au

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Australian Market Performance

7 Days: -0.2%
3 Months: 5.5%
1 Year: 8.6%
Year to Date: 5.1%

The market has been flat in the last week, however the Materials sector is down 4.2%. More promisingly, the market is up 8.6% over the past year. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›

💥 How Agentic AI Could Change Every Industry

Richard Bowman

August 2025

This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.

Last Week

CSL Stock Price